Antibody Molecular Dynamics Simulation

Simulates the intrinsic flexibility of the complementarity-determining regions (CDRs) over nanosecond-to-millisecond timescales. This captures the ensemble of paratope shapes presented to the antigen, moving beyond a single static crystal structure. Key outputs include:

• CDR-H3 dynamics: The most variable loop often transitions between multiple metastable states.
• Canonical cluster validation: Verifies whether CDR-L1, L2, L3, and H1, H2 adopt standard backbone conformations.
• Solvent exposure analysis: Tracks how side-chain accessibility changes during breathing motions.

Quantifies the energetic and structural resilience of the antibody-antigen interface under thermal motion. Root-mean-square fluctuation (RMSF) and hydrogen bond occupancy are tracked to identify:

• Hotspot residues: Amino acids that contribute disproportionately to binding free energy.
• Water-mediated contacts: Solvent molecules that bridge the paratope and epitope, often critical for specificity.
• Dissociation pathways: Steered MD can pull the antigen away to calculate the rupture force and map the energy barrier to unbinding.

Models the effect of protonation state changes on antibody structure, crucial for understanding FcRn-mediated recycling. Constant-pH MD simulations allow histidine residues to titrate dynamically, revealing:

• Endosomal domain dissociation: How the Fc region releases the receptor at acidic pH.
• Antibody-drug conjugate (ADC) linker stability: Whether acid-labile linkers remain intact during intracellular trafficking.
• Aggregation propensity shifts: How low-pH formulation conditions might expose hydrophobic patches.

Evaluates how the conserved N297-linked glycan in the Fc region modulates conformational dynamics and effector function. Simulations with explicit glycan force fields (e.g., GLYCAM) reveal:

• FcγR accessibility: How specific glycoforms (e.g., afucosylated) shift the Fc conformation to enhance ADCC.
• Quaternary structure stabilization: How the glycan bridges the two CH2 domains, maintaining the Fc in an open, active state.
• Glycan shielding effects: How terminal sialic acid residues mask protein surfaces to reduce immunogenicity.

Calculates the relative binding free energy (ΔΔG) of antibody mutants with high precision. Alchemical FEP simulations gradually transform one residue into another within the binding interface, providing:

• In silico deep mutational scanning: Ranks hundreds of potential CDR mutations by predicted affinity gain.
• Specificity profiling: Predicts whether a mutation that improves target binding also increases off-target cross-reactivity.
• Mechanistic insight: Decomposes ΔΔG into van der Waals, electrostatic, and solvation contributions to guide rational design.

Uses coarse-grained and all-atom MD to simulate the early stages of antibody aggregation, a critical developability risk. Multiple copies of the antibody are simulated at high concentration to identify:

• Aggregation-prone regions (APRs): Short hydrophobic stretches that drive self-association.
• Dimerization interfaces: Whether aggregation initiates via Fab-Fab, Fab-Fc, or Fc-Fc contacts.
• Formulation excipient effects: How arginine or sucrose molecules disrupt protein-protein contacts to stabilize the monomeric state.

The computational identification of the specific amino acid residues on an antigen that are recognized by an antibody's paratope. MD simulations contribute by revealing conformational epitopes—residues that are not contiguous in sequence but become spatially adjacent upon folding. Dynamic epitope mapping via simulation can identify:

• Residues with high per-residue energy decomposition contributions to binding
• Cryptic epitopes that are transiently exposed during protein breathing motions
• Allosteric effects where antibody binding at one site modulates distant conformational dynamics

The machine learning-guided process of iteratively introducing mutations into CDR loops to enhance binding strength. MD simulations provide critical training data by:

• Calculating binding free energies (ΔG) via MM/PBSA or alchemical free energy perturbation
• Identifying hotspot residues where mutations yield the largest affinity gains
• Predicting entropic penalties from loop rigidification upon binding
• Screening virtual mutation libraries for improved electrostatic complementarity and van der Waals packing

A multi-parameter computational evaluation of an antibody candidate's biophysical liabilities that predict manufacturing and formulation risks. MD simulations probe:

• Aggregation propensity by exposing hydrophobic patches that are normally buried
• Chemical degradation sites, including solvent-exposed methionine oxidation and asparagine deamidation
• Conformational stability via root-mean-square fluctuation (RMSF) analysis of framework regions
• Viscosity at high concentration, modeled through protein-protein interaction simulations

The de novo computational generation of an antibody's three-dimensional structure from sequence alone, with special focus on the hypervariable CDR-H3 loop. While tools like IgFold provide rapid predictions, MD simulations serve as a critical validation step by:

• Relaxing predicted structures to eliminate steric clashes and bond geometry violations
• Sampling the conformational ensemble of flexible CDR-H3 loops that may adopt multiple states
• Assessing whether predicted structures remain thermodynamically stable over simulation time
• Generating physiologically relevant conformations for downstream docking studies

The rational modification of the antibody's constant region to modulate effector functions or enhance pharmacokinetics. MD simulations elucidate:

• FcRn binding dynamics at endosomal pH 6.0 versus physiological pH 7.4, critical for half-life extension
• Fcγ receptor interface conformations that govern ADCC and ADCP potency
• Hinge region flexibility and its impact on C1q binding for complement-dependent cytotoxicity
• Heterodimerization interface stability in bispecific formats with engineered CH3 domains